Prevention of magnesium isoglycyrrhizinate for chemotherapy-induced liver damage during initial treatment of patients with esophageal cancer

Abstract

Objective To observe the preventive effect of magnesium isoglycyrrhizinate on the acute drug-induced liver damage of chemotherapy-induced initial treatment patients with esophageal cancer. Methods Eighty cases of initial treatment esophageal cancer who had definite pathological diagnosis were selected. Then they were randomly divided into the experiment group with magnesium isoglycyrrhizinate for prevention and the control group without liver protection drug. The chemotherapy regimen was the paclitaxel and cisplatin (TP scheme), and retained the serum at the time of one day before the chemotherapy and one week after the chemotherapy, then adopted the automatic biochemical analyzer to detect alanine aminotransferase (ALT), glutamic oxalacetic transaminase (AST), total bili-rubin (TBil) and alkaline phosphatase (ALP). Results Thirteen patients had abnormal performance of liver function biochemical index. Among them, there was two patients in experiment group (5.0%) and 11 patients in the control group (27.5%), and the difference of preventive effects was significant (P<0.05). One week after chemotherapy, the liver biochemical indexes in the experiment proup: ALT(21.95±6.42)U/L, AST(22.95±6.92)U/L, TBil(13.49±4.35)μmmol/L, ALP(92.58±30.50)U/L, compared with the control group, all the differences were significant (all P<0.05). Conclusions The magnesium isoglycyrrhizinate has good preventive effect on the acute drug-induced liver damage of chemotherapy-induced initial treatment patients with esophageal cancer, as it is worth to be promoted. Key words: Esophageal cancer; Magnesium isoglycyrrhizinate; Chemotherapy; Hepatic injury